Business
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 SECOND QUARTER FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter of 2025 and provided a corporate update.
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"- Sales of rhCollagen and bioinks primed for augmentation following new U.S.-based commercial executive hire -","length":115,"tagName":"p","attribs":{}},{"type":"text","content":"- Raised $3.6 million in registered direct offering in second quarter - ","length":71,"tagName":"p","attribs":{}},{"type":"text","content":"REHOVOT, Israel, Aug. 20, 2025 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived, rhCollagen for tissue regeneration and medical aesthetics, today announced financial results for the second quarter of 2025 and provided a corporate update.","length":373,"tagName":"p"},{"type":"image","alt":"Photocurable dermal filler, a product candidate currently under development.","displaySize":"","headline":null,"caption":"Photocurable dermal filler, a product candidate currently under development.","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":267,"url":"https://media.zenfs.com/en/prnewswire.com/1086eaf08794a826edde66419c8dbb87"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/APhFNT6vhm76EqUFlox7RQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ3MTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/1086eaf08794a826edde66419c8dbb87","width":400,"height":267}},"href":"https://mma.prnewswire.com/media/2753944/CollPlant.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"Yehiel Tal, CollPlant's Chief Executive Officer commented, "In recent months, CollPlant has been making strong progress with its photocurable dermal and soft tissue filler program, completing additional testing and preparing for the clinical phase. The product's superior skin-lifting, tissue-rejuvenation, and contouring capabilities have generated strong interest from leading medical aesthetics companies. We also continued to advance our regenerative breast implant program and expand distribution for our rhCollagen and bioink products in key markets. These efforts will now be led by our newly appointed, U.S.-based Head of Commercial Operations for North America."Mr. Tal continued, "To support these initiatives, we raised a modest amount of capital this quarter, providing financial flexibility while pursuing a long-term, non-dilutive transaction to dr...